Novo's Ozempic Soars As Focus Shifts To Oral Semaglutide

 
• By Kevin Grogan
  
Alarm
Novo Nordisk expecting a call soon from the FDA on oral semaglutide • Source: Shutterstock

More from Earnings

More from Business